drugset / Trial / NCT00005792
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 1
Completed
131 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb · collabSmithKline Beecham · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients who have multiple myeloma.
Timeline
- Start
- 1998-06-02
- Primary completion
- 2006-07-01
- Completion
- 2018-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | 1363 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Topotecan | Small molecule | 3.3 mg/m2 | Intravenous |